The event took a more serious approach, focused on issues relevant to immediate business
seventh edition of the annual biotechnology conference, BioAsia 2010,
the global biobusiness forum was held from February 3 to 6, 2010, in
The four-day BioAsia 2010 conference was inaugurated by K Rosaiah,
chief minister of Andhra Pradesh. After inaugurating the event he
announced that top biotechnology companies are ready to invest up to Rs
1,000 crore to create infrastructure for the plug-and-play lab in the
third phase of biotech park in the state.
He said, “On behalf of the state government, I assure full
cooperation to the investors in biotech industry to come out with
innovations and investments in the area of biotechnology not only in
generating products but also in research and exploration of new avenues
for the benefit of people.”
Some of the prominent people present at the event were Prof. Seyed E
Hasnain, chairman, BioAsia 2010 Advisory Board and vice chancellor of
the University of Hyderabad; Dr MK Bhan, secretary, Department of
Biotechnology, Government of India; Kanna Lakshmi Narayana, minister of
major industries, Government of Andhra Pradesh; Joseph Huguet I Biosca,
minister of innovation, Catalonia Government, Barcelona; Joel S Marcus,
chairman and CEO, Alexandria Real Estate Equities, US; and Dr Maive
Rute, director general, European Commission, Brussels.
Jointly organized by the Federation of Asian Biotech Associations
(FABA), State Government of Andhra Pradesh, University of Hyderabad,
and All India Biotech Association (AIBA); BioAsia had the participation
of over 2,000 delegates this year. The annual event provided the
opportunity for showcasing the initiatives taken in Andhra Pradesh to
create worldclass life science clusters in Genome Valley and in various
parts of the state.
BioAsia, which is one of the largest biotech and life sciences event in
South Asia, provided a platform for biotech companies to network,
display their technologies, and interact with the delegates. The event
this year had the presence of delegates and companies from over 30
countries including North America, Europe and Asia.
The event comprised four tracks and 24 technical sessions covering the
areas of medical biotechnology, biopharmaceuticals, agribiotechnology
and animal biotechnology. Apart from the conference sessions, the event
closed with about 500 B2B meetings. The other highlight of this
year's edition were Indo-European networking meetings, white
papers on PPP in biotechnology and funding options for drug discovery.
Delivering his lecture, Dr MK Bhan, said, “BioAsia is an
example of how connectivity can be built with companies and people
coming from different parts of the world.” He stressed that
the field of biotechnology needs technologists driving
entrepreneurship. He stated that the Indian government has been
increasing its science budget by 30 percent each year and DBT has
funded more than 120 companies in the last 12 months. The next edition
of BioAsia is scheduled for February 21-24, 2011, in Hyderabad.
Highlights of BioAsia 2010
Genome Valley Excellence
Recognizing the need to reward the stalwarts in biotech, BioAsia
presented Genome Valley Excellence Awards to Dr CR Rao, director,
Center for Multivariate Analysis, Pennsylvania State University, US,
for his research contribution to statistical methods to understand
health and disease and Janet Thornton, director, EMBL European
Bioinformatics Institute, Cambridge, UK, for her outstanding
contribution using computational methods for understanding protein
structure and its function.
Alexandria Center for
Science and Innovation
The Chief Minister unveiled the plaque to mark the inauguration of
Alexandria Center for Science and Innovation in Genome Valley, where
the company wants to invest Rs 500 crore in the biotech cluster. The
proposed center, to come up in phase III of biotech park would provide
worldclass plug-and-play lab space for biotech companies.
CEO Conclave calls for
re-evaluating business models
The CEO Conclave held as part of the seventh edition of BioAsia,
leaders of the Indian biotech industry discussed about the ways to gear
up the Indian biotech industry to face the global challenges. Sandeep
Gupta, managing director of Eli Lilly India, said, “Biopharma
companies are exploring various outsourcing and partnering models.
Bigger MNCs like Eli Lilly have changed their model from
fully-leveraged pharmaceutical model to collaboration models,
especially for a market like India. The small biotech model is now
being emulated by big pharma to reinvigorate R&D in several
Dr Rajesh Jain, managing director, Panacea Biotec, said,
“Money is not the only issue in innovation. The bigger pharma
giants have a drying R&D pipeline and productivity. We need to
leverage human minds not resources. We have to be innovative in a more
The other common points that came out in the discussion
were-need for platform technologies, a model based on risk
and reward sharing, focus on biologics, creation of autonomous
R&D units and creative funding approaches leading to newer
devices cluster in Hyderabad
Andhra Pradesh will set up MedTech Valley, a worldclass cluster for
manufacturing medical devices and equipment near Genome Valley at
Shameerpet in Hyderabad.
The state government will provide 1,200 acres of land for the project.
In the first phase, 200 acres are being developed by the Hyderabad
Metropolitan Development Authority. The project will be executed by a
public-private partnership model and will get assistance from the
Center for Infrastructure Development.
Parveen in Hyderabad